BDC on X
STLN, formerly TOI, reports rising revenue, positive free cash flow and EBITDA after a debt refinancing and rebrand. Management is positioning the former distressed equity as a growth company.
NASDAQ
Starling Oncology, Inc.
STLN
5 articles
$436M Market cap · 2026-08-24
BDC on X
Outstanding results from $STLN (formerly $TOI) https://t.co/csecGWhVFe
BDC on X
TOI says Medicare Advantage rate pressure is a growth tailwind, pushing health plans to seek its care-access and utilization-management services.
BDC on X
$STIM owns clinical distribution infrastructure for psychedelic treatments, while its stock price implies zero or negative equity value for the asset.
BDC on X
$toi https://t.co/9pfaLXskXk
